About: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Creator	Zhang, Jingyi Cheng, Zhenshun Zhang, Yongxi Huang, Jianying Yin, Ping Wang, Xinghuan Luo, Yongwen Chen, Bo Chen, Chang Chen, Song Lu, Mengxin Wu, Jianyuan
source	MedRxiv
abstract	Background No clinically proven effective antiviral strategy exists for the epidemic Coronavirus Disease 2019 (COVID-19). Methods We conducted a prospective, randomized, controlled, open-label multicenter trial involving adult patients with COVID-19. Patients were randomly assigned in a 1:1 ratio to receive conventional therapy plus Umifenovir (Arbidol) (200mg3/day) or Favipiravir (1600mg2/first day followed by 600mg*2/day) for 10 days. The primary outcome was clinical recovery rate of Day 7. Latency to relief for pyrexia and cough, the rate of auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV) were the secondary outcomes. Safety data were collected for 17 days. Results 240 enrolled COVID-19 patients underwent randomization; 120 patients were assigned to receive Favipiravir (116 assessed), and 120 to receive Arbidol (120 assessed). Clinical recovery rate of Day 7 does not significantly differ between Favipiravir group (71/116) and Arbidol group (62/120) (P=0.1396, difference of recovery rate: 0.0954; 95% CI: -0.0305 to 0.2213). Favipiravir led to shorter latencies to relief for both pyrexia (difference: 1.70 days, P<0.0001) and cough (difference: 1.75 days, P<0.0001). No difference was observed of AOT or NMV rate (both P>0.05). The most frequently observed Favipiravir-associated adverse event was raised serum uric acid (16/116, OR: 5.52, P=0.0014). Conclusions Among patients with COVID-19, Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir significantly improved the latency to relief for pyrexia and cough. Adverse effects caused Favipiravir are mild and manageable. This trial is registered with Chictr.org.cn (ChiCTR2000030254).
has issue date	2020-03-20(xsd:dateTime)
bibo:doi	10.1101/2020.03.17.20037432
has license	medrxiv
sha1sum (hex)	31ecb4b3f8518701183b17951438878162ba4699
schema:url	https://doi.org/10.1101/2020.03.17.20037432
resource representing a document's title	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
resource representing a document's body	covid:31ecb4b3f8518701183b17951438878162ba4699#body_text
is schema:about of	named entity 'Clinical Trial' named entity 'MANUSCRIPT' named entity 'LICENSE' named entity 'COUNT' named entity 'REUSE' named entity '336' named entity 'RIGHTS' named entity 'author' named entity 'word count' named entity 'Manuscript' named entity 'medRxiv' named entity 'Randomized Clinical Trial' named entity 'preprint' named entity 'COVID-19' named entity 'Wilcoxon rank sum test' named entity 'oxygen' named entity 'preprint' named entity 'preprint' named entity 'doi' named entity 'statistical sample' named entity 'mmHg' named entity 'preprint' named entity 'preprint' named entity 'peer-reviewed' named entity 'oxygen therapy' named entity 'doi' named entity 'COVID-19' named entity 'medRxiv' named entity 'mechanical ventilation' named entity 'medRxiv' named entity 'preprint' named entity '0.80' named entity 'respiratory support' named entity 'control group' named entity 'follow-up' named entity 'peer-reviewed' named entity 'mechanical ventilation' named entity 'statistical analysis' named entity 't-test' named entity 'oxygen therapy' named entity 'preprint' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'Fisher's exact test' named entity 'armpit' named entity 'inhalation' named entity 'respiratory rate' named entity 'NPPV' named entity 'coagulation' named entity 'Oxygen saturation' named entity 'preprint' named entity 'respiratory frequency' named entity 'control group' named entity 'respiratory symptom' named entity 'kPa' named entity 'cough' named entity 'oxygen saturation' named entity 'favipiravir' named entity 'respiratory failure' named entity 'oxygen' named entity 'peer-reviewed' named entity 'noninvasive positive pressure ventilation' named entity 'COVID-19' named entity 'arbidol' named entity 'inhalation' named entity 'preprint' named entity 'control group' named entity 'room temperature' named entity 'cough' named entity 'cough' named entity 'fever' named entity 'oxygen therapy' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software